Apogee Therapeutics, Inc. (NASDAQ: APGE) on Tuesday shared interim data from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma. The data covers 19 adult patients ...
Michigan researchers and doctors are improving asthma treatment with new therapies, addressing Detroit's high asthma burden.
1monon MSN
Why do most people mistake COPD for asthma? Pulmonologist explains why that delay can be deadly
Misunderstanding COPD and asthma can be risky. Recognising the difference in the condition, treatment options, and the need for early intervention is important.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results